(Alliance News) - AstraZeneca PLC on Wednesday said it won two new drug approvals in the European Union for Imfinzi and Lynparza to treat cancer. Read More
(Alliance News) - Stock prices in London opened higher on Wednesday, while official statistics showed a surge in UK government borrowing, as Westminster forks out billions for its energy support scheme. Read More
(Alliance News) - AstraZeneca PLC on Monday said it received a host of approvals or recommendations for approval for a handful of prospective treatments in the EU, but noted disappointing phase 3 trial results for Imfinzi. Read More
(Alliance News) - Stock prices in London opened higher on Monday, but the FTSE 100 was lagging behind European counterparts, despite gains for oil and mining stocks. Read More
(Alliance News) - HealthBeacon PLC on Friday said it appointed a new interim chief financial officer, while the process to appoint a CFO on a permanent basis is ongoing. Read More
(Alliance News) - C4X Discovery Holdings PLC on Thursday said its annual loss widened, but it remains positive in its outlook, citing a partner programme with AstraZeneca PLC. Read More
(Alliance News) - AstraZeneca PLC on Thursday alongside US peer Merck & Co, announced that the US Food & Drug Administration will extend the Prescription Drug User Fee Act date by three months to allow further time for a full review of the supplementary new drug application of Lynparza in combination with abiraterone and prednisone or prednisolone. Read More
(Alliance News) - Stock prices in London are set to open lower on Thursday, after the US Federal Reserve raised interest rates as expected and ahead of three more central bank decisions. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Friday said updated results from a phase 1 trial showed datopotamab deruxtecan continued to show promising responses in patients with breast cancer. Read More
(Alliance News) - AstraZeneca PLC on Friday announced that datopotamab deruxtecan has shown "encouraging and durable efficacy" in phase 1 trials. Read More
(Alliance News) - AstraZeneca PLC on Thursday releases results from trials on its breast cancer drugs camizestrant and capivasertib, both when compared to faslodex, which treats breast cancer. Read More
(Alliance News) - Stocks in London closed in the red on Wednesday, despite a strong performance from pharmaceutical stocks, as investors digested a raft of economic data from both China and Europe. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said its Enhertu drug achieved statistically significant overall survival in breast cancer patients in a recent trial. Read More
